Pfizer has made its once‑weekly GLP‑1 weight‑loss drug Xianweiying (ecnoglutide) available for pre‑order in mainland China, with shipments scheduled to begin on April 27. The drug is priced at 489 yuan (about $72) per 1.2 ml injector pen, positioning it competitively against the weekly GLP‑1 therapies of Novo Nordisk and Eli Lilly.
Xianweiying is the first Pfizer product to enter the Chinese obesity‑drug market, following a licensing agreement with Sciwind Biosciences that grants Pfizer commercialization rights in China for up to $495 million. The move aligns with Pfizer’s broader strategy to expand its metabolic portfolio in China, where the obesity‑treatment market is projected to reach several hundred million dollars by 2030 and the GLP‑1 segment to exceed $500 million.
The drug’s once‑weekly dosing schedule offers a convenience advantage over the once‑monthly claim in the original article and matches the dosing of established competitors. Xianweiying is already approved in China for type 2 diabetes, giving Pfizer a physician base and a dual‑indication advantage that could accelerate uptake in the weight‑management segment.
Competition in China is intense, with Novo Nordisk’s Wegovy and Eli Lilly’s tirzepatide already on the market, as well as local players such as Innovent Biologics. The launch of Xianweiying adds depth to Pfizer’s portfolio and positions the company to capture market share as patent expirations for existing GLP‑1 drugs approach and generic competition looms.
The pricing of 489 yuan places Xianweiying in a similar range to other GLP‑1 injectables, potentially making it an attractive option for patients and payers. However, the drug is not covered by China’s state‑run health insurance for type 2 diabetes, which may limit reimbursement and affect market penetration.
Pfizer’s entry into China reflects a broader trend of multinational pharmaceutical companies investing heavily in the country’s metabolic sector, with competitors like Eli Lilly and Novo Nordisk committing billions to local manufacturing and R&D. The launch of Xianweiying is a strategic step that could enhance Pfizer’s competitive positioning and revenue potential in a high‑growth market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.